Chaim Shustik
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.
Journal: Cancers
Published: June 11, 2023
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
Journal: Future oncology (London, England)
Published: February 23, 2023
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 04, 2021
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.
A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma.
Journal: American journal of hematology
Published: September 16, 2021
Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
Journal: Cancer medicine
Published: March 13, 2020
Spontaneous remission and clonal evolution in lenalidomide associated secondary AML.
Journal: Leukemia & lymphoma
Published: February 21, 2020
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Journal: Hematological oncology
Published: December 20, 2019
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Journal: The New England journal of medicine
Published: June 02, 2018
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Journal: British journal of haematology
Published: December 21, 2016
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.
Journal: Annals of hematology
Published: September 21, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Journal: The Lancet. Oncology
Published: July 28, 2016
Last Updated: 09/26/2026